Image credit- shutterstock.com
PharmaJet®, the maker of innovative, needle-free injection technology based in the US, has announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea.
The consortium also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology.
Genexine’s GX-19 vaccine was approved for a Phase I/IIa trial in June by South Korea’s MFDS (Ministry of Food and Drug Safety).
The clinical trial of GX-19, the first human study of a COVID-19 preventive vaccine in Korea, is underway and is assessing the safety, tolerability, and immunogenicity in sixty healthy adults aged 19-50 years in Phase 1, and will further expand to enroll an additional 150 people in Phase IIa, to be conducted in Korea this fall.
